Teleflex Incorporated TFX recently unveiled the UroLift Advanced Tissue Control (ATC) System and the UroLift 2 System together with real-world data presentations at the American Urological Association ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Investigators proposed criteria to define procedural success after minimally invasive surgical treatments (MISTs) for benign prostatic obstruction (BPO).

With more than 40 million men dealing with an enlarged prostate (BPH), chances are either you or someone you know is experiencing the frequent urge to go to the bathroom or slowed urinary flow. For 69 ...

KEARNEY, Neb., May 9, 2018 /PRNewswire-PRWeb/ -- Kearney Urology today announced that Dr. Pohlman has been designated as a UroLift® Center of Excellence. The designation recognizes that Dr. Pohlman ...

PLEASANTON, Calif., March 24, 2020 /PRNewswire-PRWeb/ -- NeoTract, a wholly owned subsidiary of Teleflex Incorporated (NYSE:TFX) focused on addressing unmet needs in the field of urology, today ...

DEAR DR. ROACH: I’m 79, and for several years, I have been taking finasteride and tamsulosin for benign prostatic hyperplasia. (In the past, I underwent a TURP procedure, which I will never go through ...

WAYNE, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX), a leading global provider of medical technologies, announced today that a new peer-reviewed study in the Nature journal ...

PLEASANTON, Calif.--(BUSINESS WIRE)--NeoTract, Inc., today announced that the UK’s National Institute for Health and Clinical Excellence (NICE) has issued an interventional Procedure Guidance (IPG) ...

Urolift is a minimally invasive procedure to help treat an enlarged prostate, known as benign prostatic hyperplasia (BPH). Medicare will typically cover Urolift procedures when a doctor deems them ...

Teleflex IncorporatedTFX recently released favorable results of multiple studies on the company's minimally invasive treatment for enlarged prostate, also known as BPH (benign prostatic hyperplasia).

NICE commissioned an external assessment centre (EAC) to review the evidence submitted by the company. This section summarises that review. Full details of all the evidence are in the project ...